Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEL-105
- Development stage
- Preclinical
- Lead developer
- Celista Pharmaceuticals
- Modality
- Small Molecules
01
Overview
CEL-105 is a small molecule therapeutic candidate being developed by Celista Pharmaceuticals for the treatment of Hypoactive Sexual Desire Disorder (HSDD). The asset involves the repurposing of an already approved small molecule drug, utilizing Celista's proprietary formulation and device technologies to optimize delivery for this new indication. By leveraging an established safety profile of an existing drug and applying novel delivery methods, CEL-105 aims to provide a more effective or better-tolerated treatment option for women experiencing HSDD. The project is currently in the Pre-IND (Investigational New Drug) phase of development.
Beyond the preview
Go deeper on CEL-105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEL-105.